Current guidance states that prophylaxis with human normal immunoglobulin (HNIG) is not usually required in infants under six months of age, as they are likely to be protected by maternal antibodies.
The researchers propose that guidance should be changed to recommend passive immunisation with HNIG for most infants exposed to measles below six months of age.